loginregister

cart

0.00 €
HPLC testedCOA every batchEU shippingSEPA · secure paymentResearch Use Only
PEPTIQA BIOTECHTirzepatide10 mgPurity 98.5% · RUO

Excellent

Rating 5.0 / 5 — early quality score

★Peptiqa Reviews

Early quality score — buyers can leave a review after verified purchase.

Tirzepatide

10 mg98.5% purityLot #TIRZEP-2026-001

SKU of selected dimension: PEP-TIRZ-10MG

Tirzepatide is an innovative dual incretin receptor agonist that simultaneously targets both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. Unlike traditional GLP-1 agonists that focus on a single pathway, Tirzepatide engages two complementary metabolic signaling systems at the same time, creating a synergistic effect that surpasses the outcomes typically achieved through single-receptor activation. Activation of the GIP receptor supports enhanced lipid utilization and promotes fat oxidation within adipose tissue, while stimulation of the GLP-1 receptor helps regulate appetite, improve satiety, and optimize blood glucose control. One of the most significant studies evaluating Tirzepatide, the SURMOUNT-1 Phase III trial published in the New England Journal of Medicine, reported body weight reductions reaching 22.5% over a 72-week period, establishing Tirzepatide as one of the most effective metabolic peptides investigated to date. Additional clinical findings have demonstrated favorable effects on liver fat accumulation, blood pressure regulation, triglyceride levels, and broader metabolic health markers.
€267.18incl. VAT
✅ In Stock (40)

Volume pricing

QuantityUnit priceSavings
1 vial267.18 €—
3 vials (−7%)248.88 €−7%
5 vials (−12%)235.46 €−12%
Purchase & earn 219 points!

Ratings & reviews

Log in to rate this product after your order arrives. login

Certificate of Analysis

Lab Verified
✓View certificate before purchase — transparency guaranteed
Research Profile

Tirzepatide — scientific profile

Content is for educational and research purposes. Research Use Only.

  • Tirzepatide is an innovative dual incretin receptor agonist that simultaneously targets both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. Unlike traditional GLP-1 agonists that focus on a single pathway, Tirzepatide engages two complementary metabolic signaling systems at the same time, creating a synergistic effect that surpasses the outcomes typically achieved through single-receptor activation.
  • Activation of the GIP receptor supports enhanced lipid utilization and promotes fat oxidation within adipose tissue, while stimulation of the GLP-1 receptor helps regulate appetite, improve satiety, and optimize blood glucose control. One of the most significant studies evaluating Tirzepatide, the SURMOUNT-1 Phase III trial published in the New England Journal of Medicine, reported body weight reductions reaching 22.5% over a 72-week period, establishing Tirzepatide as one of the most effective metabolic peptides investigated to date. Additional clinical findings have demonstrated favorable effects on liver fat accumulation, blood pressure regulation, triglyceride levels, and broader metabolic health markers.

More from Metabolizem

BPC-157
BPC-157
€114.68
TB-500
TB-500
€119.56
Glutathione
Glutathione
€87.84
GHK-Cu
GHK-Cu
€103.70

This site uses cookies

Accept